A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 01 May 2018
Price : $35 *
At a glance
- Drugs Antroquinonol (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Golden Biotechnology Corporation
- 31 Aug 2018 Biomarkers information updated
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.
- 10 Oct 2017 Status changed from planning to not yet recruiting.